SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD).

SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD). Clin Pharmacol Ther. 2013 Aug 13; Authors: Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M Abstract The study aimed to determine whether patients with statin-induced myopathy could be identified using the United Kingdom Clinical Practice Research Datalink (CPRD), DNA obtained, and thereby replicate previously reported associations of statin myopathy with the SLCO1B1 c.521T>C and COQ2 rs4693075 polymorphisms.Seventy seven statin-myopathy patients (serum CPK>4xULN) and 372 statin-tolerant controls were identified and recruited. Multiple logistic regression analysis showed SLCO1B1 c.521T>C SNP to be a significant risk factor (p=0.009) with an odds ratio per variant allele of 2.06 (1.32-3.15) for all myopathy and 4.09 (2.06-8.16) for severe myopathy (CPK>10xULN, and/or rhabdomyolysis) (n=23). COQ2 rs4693075 was not associated with myopathy. Meta-analysis showed the association between c.521C>T and simvastatin-induced myopathy, though power for other statins was limited.Our data replicate the association of SLCO1B1 variants with statin-induced myopathy. Furthermore, we demonstrate how electronic medical records provide a time and cost-efficient means of recruiting severe adverse drug reactions patients onto pharmacogenetic studies.Clinical Pharmacolog...
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Pharmacol Ther Source Type: research